返回 
加入收藏
艾托格列净对索拉非尼和多纳非尼在大鼠体内药动学的影响及机制研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 艾托格列净对索拉非尼和多纳非尼在大鼠体内药动学的影响及机制研究 |
| TITLE： | Effect and mechanism of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats |
| 摘要： | 目的 研究艾托格列净对索拉非尼和多纳非尼在大鼠体内药动学的影响，并探究相关机制。方法将24只雄性SD大鼠随机分成4组，每组6只。A、B组大鼠连续7d分别灌胃0.5%羧甲基纤维素钠和艾托格列净（1.5mg/kg），第7天给药后均灌胃索拉非尼（100mg/kg）；C、D组大鼠前7d灌胃处理分别与A、B组一致，在第7天给药后均灌胃多纳非尼（40mg/kg）。各组大鼠于索拉非尼或多纳非尼给药前和给药后不同时间点采集血样，采用超高效液相色谱-串联质谱法分别测定A、B组大鼠血浆中索拉非尼质量浓度和C、D组大鼠血浆中多纳非尼质量浓度，利用DAS2.1.1软件计算药动学参数。另取6只大鼠随机分为空白对照组和艾托格列净给药组，每组3只。空白对照组大鼠灌胃0.5%羧甲基纤维素钠，艾托格列净给药组大鼠灌胃艾托格列净（1.5mg/kg），每天1次，连续7d。末次给药后，检测大鼠肝脏和小肠组织中尿苷二磷酸葡萄糖醛酸转移酶1A7（UGT1A7）、乳腺癌耐药蛋白（BCRP）和P-糖蛋白（P-gp）mRNA表达水平。结果与A组比较，B组大鼠血浆中索拉非尼的药-时曲线下面积（AUC0-）、tAUC0-∞、峰浓度（cmax）、达峰时间（tmax）、平均滞留时间（MRT0-）、tMRT0-∞均显著降低（P＜0.05），清除率（CL）和表观分布容积（V）均显著升高（P＜0.05）；与C组比较，D组大鼠血浆中多纳非尼的AUC0-t、AUC0-∞、cmax、tmax、MRT0-t均显著降低（P＜0.05），V和CL均显著升高（P＜0.05）。连续7d灌胃艾托格列净对大鼠肝脏和小肠组织中UGT1A7、P-gp、BCRPmRNA的表达无显著影响。结论艾托格列净可影响索拉非尼和多纳非尼在大鼠体内的药动学过程，减少两者的体内暴露量，但其作用机制可能并非是通过调控相关代谢酶和转运体；临床联合用药时应警惕药物治疗效果不佳可能导致的疾病进展。 |
| ABSTRACT： | OBJECTIVE To investigate the effects of ertugliflozin on pharmacokinetic of sorafenib and donafenib in rats and explore the mechanism. METHODS Twenty-four male SD rats were randomly divided into four groups， with 6 rats in each group. Groups A and B were respectively gavaged with 0.5% sodium carboxymethyl cellulose solution and ertugliflozin （1.5 mg/kg） for 7 consecutive days， and both were given sorafenib （100 mg/kg） on the 7th day. Groups C and D were administered intragastrically in the same way as those in Groups A and B， respectively， for the first 7 days； after the drug administration on the 7th day， all rats in Groups C and D were further gavaged with donafenib （40 mg/kg）. Blood samples were collected at different time points before and after administration of sorafenib or donafenib， the concentrations of sorafenib in plasma of rats in groups A and B and donafenib in groups C and D were determined by UPLC-MS/MS method. The pharmacokinetic parameters were calculated by DAS 2.1.1 software. Six additional rats were randomly divided into blank control group and ertugliflozin group， with three rats in each group. Blank control group was given 0.5% sodium carboxymethyl cellulose intragastrically， while rats in ertugliflozin group were given ertugliflozin （1.5 mg/kg） once a day for 7 consecutive days. After the last administration， the mRNA expression levels of uridine diphosphate glucuronosyl transferase 1A7 （UGT1A7）， breast cancer resistance protein （BCRP）， and P-glycoprotein （P-gp） in the liver and small intestine tissues of the rats were detected. RESULTS Compared with group A， the AUC0-t， AUC0-∞， cmax， tmax， MRT0-t and MRT0-∞ of sorafenib in group B were decreased significantly， while CL and V were increased significantly. Compared with group C， the AUC0-t， AUC0-∞ ， tmax， cmax and MRT0-t of Δ donafenib in group D were decreased significantly， while V and CL were increased significantly （P＜0.05）. mRNA expression of UGT1A7， P-gp and BCRP in the liver tissue and small intestine of rats were not significantly affected after intragastric administration of ertugliflozin for 7 consecutive days. CONCLUSIONS Ertugliflozin can affect the pharmacokinetics of sorafenib and donafenib in rats and decrease the plasma exposure of them significantly. However， its mechanism of action may not be through the regulation of related metabolic enzymes and transporters. When using drugs in combination clinically， one should be vigilant about the potential for disease progression due to poor therapeutic effects. |
| 期刊： | 2025年第36卷第07期 |
| 作者： | 邓艳茹；王智；曹格溪；闫彬；李颖；董占军 |
| AUTHORS： | DENG Yanru，WANG Zhi，CAO Gexi，YAN Bin，LI Ying，DONG Zhanjun |
| 关键字： | 艾托格列净；索拉非尼；多纳非尼；药动学；超高效液相色谱-串联质谱法 |
| KEYWORDS： | ertugliflozin； sorafenib； donafenib； pharmacokinetics； UPLC-MS/MS |
| 阅读数： | 6 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
